Atossa Genetics Inc (NASDAQ:ATOS) Continuing Upward Move

Atossa Genetics Inc (NASDAQ:ATOS)

Atossa Genetics Inc (NASDAQ:ATOS) stock fell on the open then rallied on heavy volume to finish the day with a 29% gain – closing at $0.62. ATOS shareholders have seen the stock move up by 24% for the week on the back of a company announcement that the Ernest Mario School of Pharmacy at Rutgers, The State University at New Jersey, plans to conduct a study utilizing Atossa’s intraductal microcatheter technology. Atossa Genetics is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions.

Atossa Genetics Inc (NASDAQ:ATOS)

Rutgers Study

The Rutgers program is in the research and development phase and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body. Studies demonstrating safety and efficacy, among other things, and regulatory approvals will be required before commercialization. The Rutgers researchers believe that directly administering drugs into the breast duct where breast cancer grows, by inserting microcatheters into the nipple, is a better alternative than systemic administration, because the drugs will be directly delivered to the tissue. The Rutgers program uses a unique directed delivery system comprised of nanoscale pharmaceutical carriers loaded with single drugs.

Steven Quay, MD, PhD, Atossa CEO and President of Atossa Genetics Inc (NASDAQ:ATOS) stated in a press release “We are encouraged that a leading research institution like Rutgers recognizes the potential merit of our microcatheter technology. Atossa fully supports additional research utilizing our patented microcatheter technology,”.

ATOS Stock Performance

Although down over 65% for the year, in the past quarter ATOS shareholder have seen their stock gain over 60%. Currently ATOS stock is about double its 52-week low of $0.32 but still far from its 52-week high of $2.60.

Atossa Genetics Inc (NASDAQ:ATOS) has posted no sales over the past three years. On the plus side, it has seen shrinking losses over the past four years and in 2016 reported a per share loss of (-$2.16). However ATOS shareholders should be aware that the number of outstanding shares has increased every year – resulting in shareholder’s equity being diluted. According to reports, ATOS has a consensus 1-year price target among analysts of $26.25.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Stock Making New Run

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have rallied two days in a row on heavy volume two weeks after reaching a new 52-week high on news of a collaboration with Merck. On October 10, 2017 Kalvista announced Merck acquired around a 10% stake for a payment of $9.1 million. That news sent the shares rocketing over 38% and establishing a new 52-week high at $15.80, but profit-takers stepped in and the shares closed just over $10. Shares traded sideways over the next eight trading days, then yesterday shares spiked again and then gapped up to open today before hitting an inter-day high of $14.46, and closing at $13.02.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Deal Terms

The collaboration between Merck and Kalvista Pharmaceuticals Inc (NASDAQ:KALV) for KVD001, the Kalvista’s investigational intravitreal injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition. Under the terms of the agreement, KalVista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that KalVista intends to commence later this year. Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has also granted to Merck a similar option to acquire investigational orally delivered molecules for DME that KalVista will continue to develop as part of its ongoing research and development activities.

KALV Stock Review

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) shareholders have had a good year and seen their shares appreciate by over 67% and over the past month KALV shares have gone up by over 62%. Kalvista reported no sales in 2015 or 2016 but for FY2017 they posted $1.5 million in sales. Their performance also jumped in the per share P&L. In 2016, the company posted its largest per share loss ever (-$18.23) but they shrank that number to a loss of (-$4.00) for FY2017. KALV shares have a Relative Strength Index figure of 79 – well into the “overbought” range.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $KALV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Third Time the Charm for One Horizon Group Inc (NASDAQ:OHGI)?

One Horizon Group Inc (NASDAQ:OHGI)

One Horizon Group Inc (NASDAQ:OHGI) shares are making their third run, since the beginning of September, to close above $1.25. On Friday, OHGI shares closed at $1.00, and quickly rose to an inter-day high of $1.34 on heavy volume before falling back to below $1.20 with 3.5 hours left in the trading day.

One Horizon Group Inc (NASDAQ:OHGI)

One Horizon Group Business

London, England-based One Horizon Group Inc (NASDAQ:OHGI) develops and licenses, globally, software for mobile voice over Internet protocol (VoIP). The company develops Horizon Platform, used to compete against the over the top provider’s applications that are running on their networks; and Horizon Call, a mobile application, which enables bandwidth-efficient VoIP calls over a smartphone. It offers retail smartphone VoIP, messaging, and advertising service under the Aishuo brand name; and software maintenance services.

One Horizon Group Inc (NASDAQ:OHGI) has a market capitalization of under $11 million. Last year it reported $1.6 million in sales which was better than 2015’s figure of $1.5 million, but far under the 2014 sales figure of $5.1 million. Worryingly, the company has a published “cash per share” figure of only $0.03.

OHGI Stock

OHGI stock is up over 40% for the quarter but is down for the year by almost 45%. However the stock is well off its 52-week low of $0.57 but around 60% below its 52-week high of $3.12. One Horizon Group Inc (NASDAQ:OHGI) cut its 2015 per share loss of (-$1.12) to (-$0.95) for 2016. Fortunately for investors, the company has been fairly steady regarding its number of outstanding shares so dilution has not been too much of an issue. Will the buying strength hold and allow the momentum to continue? The stock has a relative strength Index figure of over 71 – typically a number over 70 triggers an “overbought” status among traders.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OHGI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

SenesTech Inc (NASDAQ:SNES) Gets Boost from Distribution Agreement

SenesTech Inc (NASDAQ:SNES)

SenesTech Inc (NASDAQ:SNES) stock is up over 75% in the first 1.5 hours of trading after the company announced a national distribution agreement with Univar. The thinly traded pest-control company typically trades less than 100,000 shares per day but one hour into today’s session over 420,000 shares have exchanged hands.

Shares of SenesTech Inc (NASDAQ:SNES)

Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech stated in a press release “Univar is an excellent sales and distribution partner for SenesTech, with their extensive breadth and depth of coverage, their direct connection with the pest control operators, and their commitment to sustainability. They will immediately provide us with nationwide sales coverage and nine dedicated sales representatives. As they have assured us, as our distributor, Univar sees their role as an active partner in creating and building a market for ContraPest.”

ContraPest is a liquid fertility control bait for rodents that targets the reproductive capacity of both male and female rats, rendering them infertile.

SNES Stock Review

Shares of SenesTech Inc (NASDAQ:SNES) recently touched $1.58 which established a new 52-week low. The 52-week high, $10.69, was established in early 2017. SNES shares are down over 80% year-to-date despite having sales that have increased from $200,000 in 2014 to $300,000 in 2016. Per share losses shrunk from (-$1.80) in 2015 to (-$1.08) for 2016. Additionally, the company has managed to keep the number of outstanding shares at the same level (10.13 million) for the last three years, thereby avoiding shareholder dilution that sometimes accompanies companies in rapid growth.

Analysts have given SNES shares a 1-year consensus price target of $14 according to the NASDAQ.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SNES and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) Expanding Into Agriculture

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ)

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) shares gained 43.9% after the independent energy company announced it had entered into a merger definitive agreement with AgEagle Aerial Systems. The merger will expand the company’s footprint into the commercial agriculture drone business.

AgEagle boasts a product portfolio designed to help improve farming techniques with GPS technology and high-resolution aerial imagery. The precision agriculture sector presents unique growth opportunities given that there are more than 2.1 million farms that the combined company will be able to target.

“Our goal at EnerJex has been to maximize stockholder value and we believe AgEagle, with its strong leadership team, is well-positioned to capitalize on the fast-growing agriculture drone market,” said Louis Schott, CEO of EnerJex. “While AgEagle is focused on the agriculture market, we believe there is opportunity for drones in the oil and gas.

Investor’s reaction to the proposed merger has been positive seen by the stock breaking a key resistance level after consolodating for the better part of the year. The stock is now up by more than 30% for the year.

Merger Agreement

Under the terms of the merger agreement, EnerJex Resources Inc. (NYSEAMERICAN:ENRJ)’s Series A preferred shareholders are to own approximately 15% of the combined company. The transaction values AgEagle at $20 million prior to any financing. Each company’s board of directors have approved the proposed merger, which is set to be finalized in the fourth quarter.

However, shareholders of both EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) and AgEagle must approve the transaction before it is consummated. Other closing conditions include the raising of at least $4 million, and approval by the NYSE for the listing of the combined company’s common stock.

EnerJex has announced plans to divest its principal assets including its Kansas oil and gas properties in anticipation of the merger.

Non-Compliance Notice

Separately, EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) has received a notice of non-compliance from the NASDAQ Capital Market. The notice raises concerns about the stockholder’s equity which has fallen below the minimum $2 million requirements. The share price is another concern – it has dropped below the $1 a share bid requirement

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) has since been given until November 19, 2017, to file a detailed plan on how it plans to regain compliance before April 19, 2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ENRJ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Concordia International Corp (NASDAQ:CXRX) $2 Billion Debt Reduction Plan

Concordia International Corp (NASDAQ:CXRX)

Concordia International Corp (NASDAQ:CXRX) fell 38.7% after announcing it was taking steps to realign its capital structure. Part of the plan involves reducing existing secured and unsecured debt obligations. The company also plans to significantly reduce its annual interest expense.

Concordia International Corp (NASDAQ:CXRX)

CXRX Investor Reaction

The specialty Pharmaceutical Company has already effected a 30-day grace period to defer the payment of about $26 million of interest on its $735 million unsecured notes. Investors continue to push the stock lower even as the company moves to align its capital structure.

The stock is already down by more than 70% for the year, a sell-off that has pushed it below the $1 a share mark. Concordia International Corp (NASDAQ:CXRX) is now at risk of being delisted from the NASDAQ Capital Market as it does not meet the minimum $1 a share bid requirement.

However, the Chief Executive Officer, Allan Oberman, remains upbeat about the company’s long-term growth following the proposed recapitalization transaction. The executive expects the transaction to significantly reduce the company’s outstanding debt and annual interest cost.

“The decision to use the CBCA process to achieve our financial goals was a strategic one that we believe will protect our business, preserve our cash, and give us extra time to negotiate with lenders to ensure we achieve the best possible transaction for our Company, employees, suppliers, customers and other business partners,” said Mr. Oberman.

Recapitalization Transaction

The proposed recapitalization that Concordia International Corp (NASDAQ:CXRX) intends to implement will reduce the company’s existing debt obligations by about $2 billion. However, it may also result in diluting shareholder equity.

Concordia is currently in discussions with its lenders and advisors as it seeks to finalize the terms of the proposed transactions. The company has also obtained an interim order from the Ontario Superior Court of Justice which granted an interim stay of proceedings and protects it from any defaults.

The company had a total of $340 million in cash on hand as of the end of September 30, 2017, which is sufficient to meet financial obligations related to employees, suppliers, and customers. Concordia International Corp (NASDAQ:CXRX) is an international specialty pharmaceutical company with over 200 patented products. It operates in more than 90 countries.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CXRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) Trades Higher

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC)

BITCOIN SERVICES I COM USD0.001(OTCMKTS:BTSC) shares received a boost after bitcoin gained more than 5% in Friday’s trading session to close in on a new record high of $6000. The stock gained 8.25% to end the week at $0.0667.

Bitcoin’s impressive run has seen its market grow to about $100 billion. Initial Coin Offerings have achieved an average return of 790% over the past six months.

BITCOIN SERVICES I COM USD0.001(OTCMKTS:BTSC)

BTSC Stock Performance

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) is currently trading near a key support level at $0.06, below which the stock faces the risk of erasing a good chunk of gains accrued since the start of the year. The stock is up by more than 400% for the year after benefiting from the growing popularity of digital currencies.

However, the stock is currently trading in a range after dropping from $0.21 to current trading levels. Failure of Bitcoin Services to issue updates about its operations and prospects in the bitcoin mining business has been the biggest undoing in fueling investor concerns.

Business Update

Investor’s confidence has taken a hit as most of them switch their attention to other stocks that provide detailed information about their operations. The last update came in August when the company unveiled a new corporate website and announced the launch of its digital cash Dash that can be used to make instant private payments online or in-store using secure and open source platform.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) also announced the creation of a new subsidiary dubbed Crypto Capital Corp that was to develop a Crypto-currency wallet. The big plan was to provide a way for people to safely store multiple digital currencies in one location.

In May, the bitcoin manufacturing company announced it had begun mining Monero, one of the top digital currencies with a market cap of over $300 million. Early this year Bitcoin Services purchased four Antminer S9 bitcoin miners as it sought to support its growth prospects.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) operates three core business – bitcoin escrow services, bitcoin mining, and blockchain software development. Its principal products and services are the mining of bitcoin as well as providing escrow services for buyers and sellers and bitcoin.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BTSC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Alcobra Ltd (NASDAQ:ADHD) Teams Up With Johnson & Johnson (NYSE:JNJ)

Alcobra Ltd (NASDAQ:ADHD)

Alcobra Ltd (NASDAQ:ADHD) shares gained 5.30% as investors reacted to the signing of a worldwide license agreement between the company’s subsidiary, Arcturus, and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (NYSE:JNJ). Pursuant to the agreement, the two companies are to work together on the development and commercialization of a nucleic acid-based drug for the treatment of Hepatitis B.

Alcobra Ltd (NASDAQ:ADHD)

ADHD Stock Performance

Last week’s rally affirmed a bullish momentum on the stock that began early in the month. The stock is already up by more than 50% as it continues to trade in a strong uptrend. However, it is still down over 20% for the year.

The signing of an agreement with the Johnson & Johnson subsidiary appears to have strengthened investor confidence in the company’s long-term prospects. In addition to joining forces to develop Hepatitis B treatment, the two companies plan to expand their collaboration into other infectious and respiratory diseases.

Arcturus-Janssen Agreement

Under the terms of the deal, Arcturus is to receive an upfront cash payment and research and development support for the development of the nucleic acid-based drug. The Alcobra Ltd (NASDAQ:ADHD) subsidiary is also entitled to preclinical, development and sales milestones payments as well as royalty payments on future products developed and licensed as part of the collaboration.

Jansen Pharmaceuticals, on the other hand, is to assume the responsibility for development costs and commercialization costs associated with the program.

“Arcturus’ expertise and intellectual property in the field of RNA medicines is complemented by Janssen’s broad capabilities in clinical development, regulatory affairs, and marketing. Together we aim to bring new treatments to patients who are suffering from Hepatitis B and potentially other infectious diseases,” said Arcturus CEO, Joseph Payne.

Arcturus-Alcobra Merger

The signing of the strategic collaborations follows the merger of Arcturus and Alcobra Ltd (NASDAQ:ADHD) in an all-stock transaction last month. The merger will result in a combined company focused on the development of RNA medicines for treating infectious diseases cystic fibrosis among other rare liver diseases.

Arcturus boasts of a proprietary technology platform that incorporates Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry and nucleic acid delivery systems. The Alcobra subsidiary is applying the technology to develop RNA medicines under collaborations with the likes of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY), and the Cystic Fibrosis Foundation.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ADHD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.